Announcement • Mar 26
Propanc Biopharma Inc Establishes Multi-Year Joint Research Collaboration Agreement with the Universities of Jaén and Granada Spain Propanc Biopharma, Inc. announced that a multi-year Joint Research Collaboration Agreement has been established with the Universities of Jaén (UJA) and Granada (UGR), Spain. This is the fifth agreement between Propanc and the universities over a seventeen-year period resulting in four patent families being filed, five peer reviewed publications accepted, numerous scientific presentations delivered, as well as two PhD’s and a professorship awarded to members of the Universities’ research team members. The collaboration involves the evaluation of a senescence-modulating (i.e., anti-aging) compound to mitigate senescence and to complete experiments to further support the claims of recently filed fibrosis and cancer related patent applications, requested by Propanc Biopharma Inc. to the research group “Biological Technologies of The University of Jaén” and UGR’s Research Group, “Advanced Therapies: Differentiation, Regeneration and Cancer.” Two Postdoctoral Fellows of the UJA, Dr Maria Belén Toledo and Dr Aitor González-Titos will conduct the study, including in vitro and in vivo experiments, data analysis, and manuscript preparation. Prof. Juan Antonio Marchal Corrales, head of the Laboratory in Bio-fabrication and 3D-bioprinting of the University of Granada will oversee management of equipment and facilities necessary to perform in vitro and in vivo experiments and will be the scientist in charge of the experimental designs and project by the university. Over the next two years, the goal is to strengthen intellectual property and to better understand how PRP technology can overcome numerous resistant tumors, and additionally, rejuvenate cells to overcome age-related, chronic diseases, such as fibrosis. The market potential of PRP is significant and of a high degree of interest among the scientific community. As the company transforms into a clinical-stage R&D Company, it looks forward to possible major discoveries that broadens the therapeutic potential of PRP in several life-threatening diseases based on cell and tissue rejuvenation. Propanc Biopharma, Inc. is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread. Announcement • Mar 13
Propanc Biopharma, Inc. Targets Pancreatic Cancer Market With PRP Proenzyme Therapy Propanc Biopharma, Inc. focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, announced highlights of PRP, its lead proenzyme therapy poised to potentially disrupt the $3 billion+ pancreatic cancer treatment market—one of oncology’s most desperate battlegrounds with a grim 13% five-year survival rate. Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game: - >85% tumor growth inhibition demonstrated in preclinical pancreatic models - Forces malignant cells to differentiate—attacking cancer at its root - Reduces fibrosis and resistance markers in the tumor microenvironment - Sensitizes resistant tumors to standard chemo—higher efficacy, lower toxicity - Targets cancer stem cells to cut recurrence risk. PRP is advancing toward clinical development for advanced solid tumors, with pancreatic and ovarian cancers as initial priorities. PRP is designed to address the underlying drivers of cancer proliferation and spread. Announcement • Mar 04
Propanc Biopharma, Inc. Highlights Lead Asset PRP As Novel Therapeutic Approach For Metastatic Cancer Propanc Biopharma, Inc. focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, highlighted the potential of its lead asset, PRP, as a novel therapeutic approach to the treatment and prevention of metastatic cancer from solid tumors, especially more aggressively spreading, less differentiated tumors, which offer a poor patient prognosis. Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate stuck at just 13% and no real progress has been made in recent years. Standard treatments like chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel), targeted therapies (e.g., KRAS inhibitors), and emerging options (immunotherapies, tumor-treating fields like Optune Pax) extend life modestly but often bring harsh side effects, resistance, and limited success against this aggressive, metastasis-prone disease. PRP is a promising investigational proenzyme therapy (trypsinogen + chymotrypsinogen in a 1:6 ratio) delivered intravenously. Unlike cytotoxic drugs that kill dividing cells broadly, PRP targets cancer stem cells, blocks metastasis by suppressing epithelial-mesenchymal transition (EMT), disrupts the tumor microenvironment, curbs angiogenesis, and boosts chemosensitivity—potentially making standard treatments more effective with far less toxicity. Preclinical data shows >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler profile (no major side effects in limited prior human use). A small compassionate study (rectal version) extended survival from ~5.6 to 9 months in advanced cases. PRP could sensitize resistant tumors and cut doses/side effects. PRP offers a broader attack on stem cells and spread, not just single mutations. PRP may warm up “cold” pancreatic tumors by remodeling the microenvironment. The global pancreatic cancer treatment market is valued at ~$4,420 million in 2026 and projected to explode to $14,430 million by 2034 (CAGR ~16%), fueled by rising cases and demand for better options. Propanc is gearing up for a Phase 1b First-In-Human trial in 2026 (30–40 advanced solid tumor patients), backed by fresh funding ($100 million facility), new patents, and FDA Orphan Drug status for pancreatic cancer. 
